Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 24003 | NVL-655 ( ALK-IN-27 ) | 2739866-40-9 | ≧98.0% | .png) |
| NVL-655 is a novel, brain-penetrant, ALK-selective inhibitor that was designed to add | ||||
| 23122601 | Navacaprant ( BTRX-335140 ) | 2244614-14-8 | ≧98.0% |  |
| Navacaprant (NMRA-335140, BTRX-140) is an oral, selective, reversible, small-molecule | ||||
| 20608 | Ninerafaxstat | 2254741-41-6 | 98% Min. |  |
| Ninerafaxstat is a biochemical that decreases fatty acid oxidation and improves mitoc | ||||
| 20602 | NBI-921352 | 2154406-04-7 | 98% Min. |  |
| NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being develo | ||||
| 20559 | Navitoclax-piperazine | 2143096-93-7 | 98% Min. |  |
| Navitoclax-piperazine, also known as ABT-263-piperazine, is a Navitoclax derative and | ||||
| 20514 | NMS-293 ( NMS-P293 ) | 1606996-12-6 | ≧98.0% | _1606996-12-6.png) |
| NMS-293 is a PARP-1 inhibitor in early clinical development at Nerviano Medical Scien | ||||
| 20487 | NSC348884 | 81624-55-7 | 98% Min. |  |
| NSC348884 is a nucleophosmin inhibitor. NSC348884 also disrupts oligomer formation an | ||||
| 20486 | NSC-92828 | 13728-56-8 | 98% Min. |  |
| NSC-92828, also known as 3-Phenanthrenebutyric acid, is a Protein–protein interacti | ||||
| 20483 | NSC-45586 | 6300-44-3 | 98% Min. |  |
| NSC-45586 is a pan-PHLPP inhibitor selective for PHLPP1 and PHLPP2. | ||||
| 233141 | NXP-800 ( CCT361814 ) | 1693734-80-3 | ≧98.0% |  |
| NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. | ||||
| 20463 | Nefazodone | 83366-66-9 | 98% Min. |  |
| Nefazodone is an antidepressant. Its chemical structure is unrelated to selective ser | ||||
| 20448 | NBD-14270 | 2411819-82-2 | 98% Min. |  |
| 52014 | NXY-059 ( Disufenton Sodium ) | 168021-79-2 | ≧98.0% | .png) |
| NXY-059 ( Disufenton Sodium ) is a disulfonyl derivative of phenyl-tert-butyl nitrone | ||||
| 20411 | N-Benzyl-2,6-difluoro-3,5-dimethoxyaniline | 651734-53-1 | 98% Min. |  |
| 20402 | N-(6-bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)formamide | 1628263-77-3 | 98% Min. | formamide_1628263-77-3.png) |
| 20401 | N-(6-bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)-N-methylformamide | 1628263-96-6 | 98% Min. | -N-methylformamide_1628263-96-6.png) |
| G20383 | N,N-DIETHYL-2,6-CIS-DIMETHYLPIPERIDINIUM IODIDE | 1335241-44-5 | 98% Min. |  |
| 20290 | Navoximod free base | 1402837-78-8 (free base) | 98% Min. | |
| 21233 | NE 52-QQ57 | 1401728-56-0 | 98% Min. |  |
| NE52-QQ57 is an orally available GPR4 antagonist with an IC50 of 70 nM. NE 52-QQ57 si | ||||
| 21231 | NVS-PAK1-1 | 1783816-74-9 | 98% Min. |  |
| NVS-PAK1-1 is a a specific allosteric PAK1 inhibitor. | ||||
| 2021115 | Niraparib tosylate hydrate | 1613220-15-7 | 98% Min. | |
| Niraparib, also know as MK-4827, is an inhibitor of poly (ADP-ribose) polymerase (PAR | ||||
| 2071632 | N-(8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl-exo)-2-methylpropanamide | 376348-67-3 | 98% Min. | -2-methylpropanamide_376348-67-3.png) |
| 2071529 | NCC007 | 98% Min. |  | |
| NCC007 is a novel CKIα and CKIδ dual inhibitor. NCC007 that showed stronger period | ||||
| 2062304 | N-tert-butyl-3-[(2-chloro-5-methylpyrimidin-4-yl)amino]benzenesulfonamide | 936092-53-4 | 98% Min. | |
| 2062033 | N,N-dibenzyl-6-chloro-5-nitropyrimidine-4-amine | 882272-97-1 | 96% Min. |  |
| 2062032 | N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine | 1346133-39-8 | 96% Min. | -3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine_1346133-39-8.png) |
| 2062031 | N-(2-methylbenzyl)-4,5-dihydro-1H-imidazol-2-amine | 38941-29-6 | 98% Min. | |
| 2062010 | 5-(N-PHTHALIMIDO)-2-PENTANONE | 3197-25-9 | 96% Min. | -2-PENTANONE_3197-25-9.png) |
| 2061705 | Nintedanib esylate | 656247-18-6 | 98% Min. | |
| Nintedanib, also known as BIBF1120, is a potent inhibitor of multiple receptor tyrosi | ||||
| 2061601 | N-Fmoc-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl]-L-serine | 120173-57-1 | 98% Min. | |